{"id":"pax5-pcmx5","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Infection risk"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a multi-agent chemotherapy combination protocol used in cancer treatment. The exact composition and mechanism depend on the specific SWOG trial design, but typically involves cytotoxic agents that work through DNA damage and cell cycle disruption. PAx5/PCMx5 represents a standardized treatment regimen evaluated in phase 3 clinical trials.","oneSentence":"PAx5/PCMx5 is a chemotherapy regimen combining prednisone, doxorubicin, cyclophosphamide, and other agents designed to treat hematologic malignancies.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:25:45.626Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (specific indication dependent on SWOG trial protocol)"}]},"trialDetails":[{"nctId":"NCT01061437","phase":"PHASE3","title":"S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-06","conditions":"Helicobacter Pylori Infection","enrollment":1859}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lansoprazole: Prevacid"],"phase":"phase_3","status":"active","brandName":"PAx5/PCMx5","genericName":"PAx5/PCMx5","companyName":"SWOG Cancer Research Network","companyId":"swog-cancer-research-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PAx5/PCMx5 is a chemotherapy regimen combining prednisone, doxorubicin, cyclophosphamide, and other agents designed to treat hematologic malignancies. Used for Hematologic malignancies (specific indication dependent on SWOG trial protocol).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}